Kedrion Biopharma
Carlo Parillo serves as the Corporate Strategic Alliance Manager in Business Development & Strategy at Kedrion Biopharma since June 2018, focusing on global asset scouting for therapeutics and conducting rapid scientific diligence. Previously held roles include Global Marketing Product Manager for Immunoglobulins & Critical Care, and Open Innovation Associate, where Carlo contributed to the purification of Ceruloplasmin and the development of a fibrin patch for wound healing. Experience at GSK involved supporting PhD projects and manuscript preparation, while positions at Novartis Vaccines and CIRIO SOCIETÀ AGRICOLA S.R.L. included biotechnological research and analysis. Carlo holds a PhD in Biochemistry and Molecular Biology from Università di Siena, complemented by a Postgraduate Degree in Pharmaceutical Marketing and two master's degrees in Medical Biotechnology and Biotechnology for Health.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.